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ABSTRACT: All modern molecular biology and microbiology is under-
pinned by not only the tools to handle and manipulate microorganisms but
also those to store, bank, and transport them. Glycerol is the current gold-
standard cryoprotectant, but it is intrinsically toxic to most micro-
organisms: only a fraction of cells survive freezing and the presence of
glycerol can impact downstream applications and assays. Extremophile
organisms survive repeated freeze/thaw cycles by producing antifreeze
proteins which are potent ice recrystallization inhibitors. Here we introduce
a new concept for the storage/transport of microorganisms by using ice
recrystallization inhibiting poly(vinyl alcohol) in tandem with poly-
(ethylene glycol). This cryopreserving formulation is shown to result in a
4-fold increase in E. coli yield post-thaw, compared to glycerol, utilizing
lower concentrations, and successful cryopreservation shown as low as 1.1
wt % of additive. The mechanism of protection is demonstrated to be
linked not only to inhibiting ice recrystallization (by comparison to a recombinant antifreeze protein) but also to the
signiﬁcantly lower toxicity of the polymers compared to glycerol. Optimized formulations are presented and shown to be
broadly applicable to the cryopreservation of a panel of Gram-negative, Gram-positive, and mycobacteria strains. This
represents a step-change in how microorganisms will be stored by the design of new macromolecular ice growth inhibitors; it
should enable a transition from traditional solvent-based to macromolecular microbiology storage methods.
■ INTRODUCTION
Bacteria and their study underpin all research in infectious
diseases, microbiology, and structural and molecular biology as
well as being crucial in biotechnology and food processes
(notably probiotics). A key challenge with any biotechnology
or cell-based processes is the logisticsthe storage, transport,
distribution, and recovery of intact and viable cells suitable for
purpose, with no pheno/genotype alterations. Continuous
culture is rarely practical; thus, lyophilization and cryopre-
servation are commonly employed in both academic and
industrial settings.1,2 Cryopreservation,3,4 especially in research
laboratories, is the most commonly used, as no infrastructure
(other than a −80 °C freezer or liquid nitrogen (−196 °C)) is
required, ensuring it is easy to use, whereas lyophilization
requires optimization and more specialized equipment/
formulations. The storage of bacteria for supplements such
as probiotics is growing, and recent research into the
microbiome points toward its involvement in a host of medical
disorders including, but not limited to, irritable bowel
syndrome, depression, cardiovascular disease, and obesity,
showing the signiﬁcant need for strategies to store bacteria,5−8
especially if microbiome transplants become a reality for the
treatment of drug-resistant infections, for example.9
Cryopreservation traditionally requires the addition of
organic solvents to mitigate the damage caused by ice
formation and growth as well as membrane rupture and
osmotic stress which would otherwise lead to cell death.10,11
For mammalian cells, dimethyl sulfoxide (DMSO) is the most
widely employed cryoprotectant for both slow freezing and
vitriﬁcation (depending on the DMSO concentration), and for
bacteria, glycerol is typically used. While very successful and
used globally these are not perfect solutions. They require high
concentrations (10−25 wt %), the solvents can potentially
have cytotoxic eﬀects necessitating careful addition and rapid
removal (post-thaw) to maintain viability,12,13 and they do not
lead to quantitative recovery of all cells, as such there is a need
to investigate innovative cryopreservation methods.
Extremophile organisms have evolved many strategies to
enable them to survive in ice-rich environments, providing
inspiration for new biomimetic strategies to improve
cryopreservation.14,15 For example, Arctic ﬁsh species produce
a diverse range of antifreeze proteins (AFPs) which function to
limit ice growth by ice recrystallization inhibition (IRI).16−18
AFPs are not suitable for many applications though, as they
cannot be produced readily on a large scale, and their
secondary eﬀect of dynamic ice shaping can lead to reduced
cell recovery post-thaw.19,20 Furthermore, biomedical applica-
tions are hampered due to lack of suﬃcient immunological/
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toxicological data. Therefore, synthetic macromolecular
mimics of AFPs have emerged, which can reproduce their
properties but beneﬁt from the scalable and tunable synthesis
of synthetic polymers.18,21,22 These have been used to enhance
the cryopreservation of mammalian cells including blood,23−25
cell lines,26 and primary cells.27,28 Their primary function is ice
recrystallization inhibition, where the rate of growth (not
formation) of ice is slowed, leading to reduced cell death
during thawing. The most active polymer mimics reported to
date are based on not only poly(vinyl alcohol)29−34 but also
Safranin-O,35 poly(ampholyte)s,36,37 and glycopeptides.38
However, there are no reports, to the best of our knowledge,
on applying IRI-active materials to the challenge of bacterial
cryopreservation, with only a report of nonfreezing stabiliza-
tion due to freezing point depression, which is a distinct
process for nonfreezing storage.39
This paper takes inspiration from extremophile organisms to
demonstrate successful bacterial cryopreservation using a
unique all-polymer, glycerol-free, formulation. This formula-
tion beneﬁts from a synergistic eﬀect of an ice growth
inhibiting polymer with a secondary hydrophilic polymer, and
they outperform the current gold-standard glycerol, leading to
increased cell yields at low cryoprotectant concentrations.
■ EXPERIMENTAL SECTION
Bacteria Growth. Escherichia coli TOP10 cells, Bacillus subtilis
(WT168), and Mycobacterium smegmatis (Mc2155) were chosen for
freezing as three diﬀerent types of bacteria with diﬀerent cell
structures. E. coli and B. subtilis were grown in Lysogeny broth (LB)
medium containing 100 μg mL−1 ampicillin, and M. smegmatis was
grown in 7H9 broth base at 37 °C with a stirring rate of 180 rpm.
Ice Recrystallization Inhibition (Splat) Assay. A 10 μL droplet
of cryoprotectant in PBS solution is dropped from 1.4 m onto a glass
microscope coverslip on top of an aluminum plate cooled to −78 °C
using dry ice. Upon impact with the plate the droplet instantly freezes,
spreading out and forming a thin wafer of ice. This wafer is then
placed on a liquid nitrogen cooled cryostage cooled to −8 °C. The
wafer is then left to anneal for 30 min at −8 °C. Three photographs
are then taken of the wafer in diﬀerent locations at 20× zoom under
cross-polarizers. The longest grain crystals as well as the total number
of crystals in the image are counted using ImageJ; the area of the ﬁeld
of view divided by this number of crystals gives the average crystal size
per wafer, which is reported as a % of area compared to PBS control.
Freezing Protocols. Diﬀerent molecular weight PEGs (100 mg
mL−1; 200 Da, 400 Da, 1.5 kDa, 4 kDa, 6 kDa, and 8 kDa) and PVAs
(1 mg mL−1; 10, 23, and 31 kDa) were dissolved in PBS for
comparison in cryoprotective activity alongside poly(isopropenyl
acetate-alt-maleic anhydride) functionalized with (dimethylamino)-
ethanol (poly(ampholyte)), AFPIII, and glycerol. After growing each
of the bacteria until OD600, cells (150 μL) were added to separate
solutions of the diﬀerent cryoprotectants (150 μL) in 1.5 mL vials and
snap frozen in liquid nitrogen before thawing at 25 °C in a water bath
for 5 min. The freeze−thaw (FT) cycles were repeated seven times,
and then the samples were added to LB in 96-well plates (200 μL).
Serial dilutions took place, and the samples were plated on ampicillin
plates. These were left to grow at 37 °C for subsequent colony counts.
Confocal microscopy was performed to evaluate the number of live/
dead cells obtained. When storage at −20 °C was to be assessed,
samples were prepared similarly up until they were snap frozen in
liquid nitrogen, after which they were directly stored at −20 °C.
Cryoprotectant Toxicity. Equal volumes of bacteria and
cryoprotectant solutions were left shaking at 4 °C overnight. The
cryoprotectant samples (20 μL) were then added to LB in wells (200
μL) in the ﬁrst column of 96-well plates, and serial dilutions of the
samples were produced by transferring 20 μL from column 1 to
column 2, mixing, and then taking 20 μL from column 2 to column 3.
This was repeated until column 7 was reached, giving dilutions up to
10−7. Dilutions 10−2−10−5 were plated on ampicillin plates, and
colonies were grown at 37 °C for subsequent counting. Toxicity
assays were repeated using three PEG concentrations (100, 50, and 10
mg mL−1) combined with a constant PVA concentration of 0, 1, or 10
mg mL−1.
Cellular Growth Proﬁle. Toxicity and protection of cells in liquid
culture were studied using absorbance spectroscopy. Samples were
prepared as before and underwent seven FT cycles. The cells were
then grown in LB (200 mL) over 14 h under continuous shaking at 37
°C, and their OD was measured at 600 nm at 10 min intervals and
compared to a control sample that underwent no freeze−thaw cycles.
This growth assay was performed also on cells combined with
diﬀerent AFP concentrations (0.1, 2.5, and 5 mg mL−1) for
comparison as well as samples frozen at −20 °C as well as −196 °C.
Live/Dead Bacterial Viability Test. Following seven freeze−
thaw cycles using the indicated conditions, samples were isolated at
10000g for 10 min, and the supernatant was discarded. An aliquot was
taken prior to the freeze−thaw cycle as a live cell control, and a
further aliquot was heat killed (incubated at 80 °C for 30 min) for a
dead cell control. Cells were resuspended in 20 μL of 0.85% NaCl
solution. 10 μL of this suspension was diluted in 200 μL of 0.85%
NaCl solution, and the samples were incubated at room temperature
for 1 h. Samples were pelleted at 10000g for 10 min, the supernatant
was discarded, and the cells were resuspended in 100 μL of 0.85%
NaCl solution. Next, the LIVE/DEAD bacterial viability staining
mixture was prepared by mixing SYTO-9 and propidium iodide to
ﬁnal concentrations of 1.67 and 10 mM, respectively. The cells were
stained by adding 0.3 μL of the staining solution to 100 μL of cell
suspension and incubating in the dark for 15 min (at room
temperature). Slides for microscopy were prepared by trapping 5
μL of the stained bacterial suspension between a slide and a coverslip.
Samples were then analyzed by means of ﬂuorescent microscopy (at
either 100× or 60× magniﬁcation) using GFP (excitation 470/40 nm,
emission 525/50 nm) and mCherry (excitation 560/40 nm, emission
630/75 nm) ﬁlter sets to visualize the SYTO-9 and propidium iodide
staining, respectively.
■ RESULTS AND DISCUSSION
The primary aim of this study was to evaluate the role of ice
recrystallization inhibiting (IRI) polymers to enable solvent-
free cryopreservation of bacteria. A range of synthetic polymers
were selected for this based on their previous use in
mammalian cell cryopreservation: poly(vinyl alcohol), PVA,
which is a potent IRI; poly(ethylene glycol), PEG, which has
no IRI but was chosen to provide a hydrophilic “bulking” agent
which has been shown to be important for blood cell
cryopreservation;40,41 a poly(ampholyte) (p(amph)), which
has a weaker IRI activity than PVA;25,42 and recombinant
AFPIII, an antifreeze protein originally isolated from ocean
pout43 (Figure 1A). It is important to note that PVA and PEG
were particularly of interest as they are low-cost (comparable
to glycerol), are available in a range of molecular weights, and
are produced to food/clinical grades, making them ideal for
translational applications.44 The polymers’ IRI activity was
evaluated by a modiﬁed splat assay (Figure 1B−G). Brieﬂy, ice
wafers were nucleated to give small (<10 μm) ice crystals,
which were allowed to grow for 30 min and then measured.
Smaller ice crystals indicated more IRI activity, reported as the
mean largest grain size (MGLS). The concentrations chosen
for the IRI assays related to those used in cryopreservation
experiments. Detailed studies on their IRI activity have been
reported previously, and a comparison is shown in Figure S3
(Supporting Information).29,36
To evaluate the performance of these IRI active polymers
versus glycerol, a series of cryopreservation experiments were
undertaken. E. coli was added to diﬀerent cryoprotective
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formulations and then exposed to seven freeze−thaw cycles
from liquid nitrogen (−196 °C) to room temperature (20 °C),
and the number of colony forming units determined by growth
on agar plates for 16 h was recorded (Figure 2A). This was
chosen to mimic laboratory conditions where stocks are often
frozen and thawed during routine use. 25% glycerol resulted in
an average of 15 recovered colonies compared to 1 for no
added cryoprotectant. PVA, AFP, and the poly(ampholyte)
alone gave results identical to those with no cryoprotectant
added. (It should be noted that the concentrations of each of
the above were chosen based on their relative IRI activity to
give similar eﬀects, not at equal mass concentration to enable
us to correlate the physical properties to the observed
biological responses.) Our previous work using red blood
cells (which also have no nucleus, like bacteria) has shown that
IRI active polymers increased post-thaw recovery only when
used in combination with a hydrating secondary cryoprotec-
tant such as polymer gels or hydroxyethyl starch.40,41 PEG was
therefore added (due to biocompatibility and commercial
availability), and the mixture PEG/PVA (100 mg mL−1 + 1 mg
mL−1) was found to dramatically increase recovery to 69
colony forming units, which is a >4-fold increase compared to
glycerol alone. PEG/AFP mixtures lead to similar results (52
colonies), supporting the hypothesis that controlling IRI is the
key mechanism in protecting bacteria during cryopreservation,
by reducing ice growth especially during thawing. The
poly(ampholyte)s, however, showed no cryoprotective eﬀect,
despite them previously being used for mammalian cells, where
they appear to function via cell membrane interactions.37
Poly(ampholyte)s have far weaker IRI than PVA or AFPs, and
hence this supports a mechanism of protection based on
limiting ice recrystallization rather than membrane plasticiza-
tion/stabilization. In order to test whether there is a signiﬁcant
diﬀerence between the recovery obtained from PEG/PVA
versus that obtained from PVA alone, a two-sample t test was
performed, and it was concluded that the diﬀerence between
them was statistically signiﬁcant (Tables S1 and S2, Supporting
Information).
A key challenge associated with the use of glycerol is its
intrinsic toxicity at cryopreservation concentrations, so the
impact of incubating the polymers with E. coli compared to
glycerol was evaluated. Each component (at the indicated
cryopreservation concentration) was incubated with E. coli
overnight at 4 °C, and subsequently the number of colony
forming units was determined (Figure 2B). Glycerol at 15 or
25 wt % led to a signiﬁcant reduction in recovered colonies.
Conversely, none of the polymers showed toxicity to the E. coli.
The increase in recovered colonies for PVA could be due to
some metabolism of the polymer. This supports our hypothesis
that biomimetic macromolecular antifreezes are “spectator
additives” which only function when ice is present and are
Figure 1. Cryoprotectants used and IRI activity at concentrations
relevant for this work. (A) Chemical structures. Cryomicrographs of
ice wafers grown in the presence of (B) 100 mg mL−1 4 kDa PEG + 1
mg mL−1 10 kDa PVA, (C) 1 mg mL−1 10 kDa PVA, (D) 100 mg
mL−1 4 kDa PEG, (E) 1 mg mL−1 AFPIII, (F) 50 mg mL−1
poly(ampholyte), and (G) PBS control. Scale bar = 100 μm.
Figure 2. (A) Recovered colonies of E. coli after seven freeze (−196
°C)−thaw (20 °C) cycles. (B) Recovered colonies of E. coli after
overnight incubation with cryoprotectants. Concentrations of
cryoprotectants: [glycerol] = 25 wt %; [AFPIII] = 1 mg mL−1;
[PVA] = 1 mg mL−1; [PEG/AFPIII] = 100 + 0.01 mg mL−1; [PEG/
PVA] = 100 + 1 mg mL−1; [poly(ampholyte)] = 50 mg mL−1).
Control is LB media alone.
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ignored by microorganisms (and indeed other cells) which is
crucial for downstream applications.
To further optimize this formulation, the PEG concentration
was varied from 100 to 10 mg mL−1, all with addition of 1 mg
mL−1 PVA, and the number of recovered colonies after seven
freeze−thaw cycles was counted (Figure 3A). Reducing the
concentration of PEG to 50 and 10 mg mL−1 led to a
signiﬁcant reduction in the number of colonies recovered
compared to 100 mg mL−1. However, it is important to note
that 10 mg mL−1 PEG with 1 mg mL−1 PVA is just a 1.1 wt %
solution but performs equally to 25 wt % glycerol, which
represents a remarkable cryopreservation outcome with a 25-
fold reduction in cryoprotectant. It shows that while there is an
optimum formulation, there is scope to vary the components
and hence supporting ease of use in a realistic laboratory
situation. In some downstream applications (such as food)
lowering cryoprotectants concentration, rather than max-
imizing total cell recovery, is desirable, and this new
polymer-only formulation is clearly suitable.
The above experiments relied on counting colony-forming
units, which shows the application but does not give insight
into the mechanisms of cell stress during freeze−thaw. To
assess the bacteria immediately after thawing, confocal
microscopy was employed with a live/dead viability assay
which measures the integrity of cell membranes (Figure 3B
and Figure S11). Bacterial cells with intact cell membranes
exhibit green ﬂuorescence (SYTO-9 dye) while those with
compromized cell membranes exhibit red ﬂuorescence
(propidium iodide dye). Following freeze/thaw in PBS alone
just 2.2% of the E. coli had intact membranes (green),
demonstrating that ice growth causes signiﬁcant mechanical
damage. Post-freeze/thaw in either 25% glycerol or PEG/PVA
resulted in 15−18% of the E. coli retaining intact membranes.
These observations suggest that the mechanisms of cryoinjury
of both glycerol and our macromolecular antifreezes are very
similar. However, the colony counting results (Figure 2)
conﬁrmed the polymer approach to be superior, supporting a
hypothesis that the reduced toxicity of the polymers means
that more and healthier colonies can grow post-thaw, and
reduced growth inhibition compared to glycerol.
Additional bacterial strains for cryopreservation were
selected to cover a wide range of genera to ensure these
eﬀects are not unique to E. coli. Bacillus subtilis was chosen as a
Gram-positive strain and Mycobacterium smegmatis as a
mycobacteria (distinct cell wall compared to other Gram-
positives) for further analysis. Using the same conditions as for
E. coli, the cells were exposed to seven freeze−thaw cycles, and
the recovered colonies were counted (Table 1). To enable
comparison of the data and to account for the diﬀerent growth
rates of each bacterial strain, the recovered colonies were also
normalized to the highest recovery (Figure 4).
In all cases, the PEG/PVA mixture gave equal or better
levels of recovery than glycerol alone. It was noted that M.
smegmatis (which is a slow-growing organism compared to
other two) gave fewer colonies after a ﬁxed period of growth in
all conditions, but the PEG/PVA still matched the perform-
ance of glycerol. In some cases, the PEG alone gave favorable
recovery levels also (as any uncharged solute will give some
protection), but in all cases addition of PVA increased this
recovery, showing it is an essential component to ensure
recovery of viable cells, without resorting to multiple rounds of
Figure 3. (A) Eﬀect of varying PEG concentration on number of
recovered E. coli colonies after seven freeze (−196 °C)−thaw (20 °C)
cycles. (B) Live/dead viability testing on E. coli immediately after
freeze−thaw cycle, with percentage of green (intact membrane)
bacteria determined by confocal microscopy. [PEG/PVA] = 100 + 1
mg mL−1. Error bars represent SD from six repeats.
Table 1. Mean Colonies Recovered after Seven Freeze−Thaw Cyclesa
E. coli M. smegmatis B. subtilis
total normalized (%) total normalized (%) total normalized (%)
control 1 ± 0.4 1 4 ± 0.5 12 29 ± 10.4 11
25% glycerol 15 ± 2.8 22 30 ± 6.0 88 93 ± 18.9 35
AFPIII 3 ± 0.9 4 2 ± 0.3 6 26 ± 6.7 10
PVA 0 ± 0.1 0 3 ± 1.5 9 5 ± 0.7 2
PEG 53 ± 6.7 77 28 ± 4.3 82 150 ± 10.7 57
PEG/PVA 69 ± 7.3 100 34 ± 4.2 100 262 ± 39.3 100
poly(ampholyte) 5 ± 0.6 7 28 ± 4.5 82 20 ± 5.0 8
a[Glycerol] = 25 wt %; [PEG] = 100 mg mL−1; [PEG/PVA] = 100 + 1 mg mL−1; [AFPIII] = 0.1 mg mL−1; poly(ampholyte) = 50 mg mL−1. Error
represents the SD from six repeats. Note that the total colonies recovered for each organism vary based on their own growth rates; hence,
normalized recovery (versus the highest recovery level) is also included.
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freezing controls. These results demonstrate the versatile
nature of this approach and that replacing glycerol in
laboratories with this polymer formulation is a reliable way
to match or improve current storage methods.
This macromolecular cryoprotection solution using ice-
inhibiting polymers is clearly suitable for bacteria storage, but
there are many parameters which can be varied in this system
including the molecular weight of the polymers and weight
ratios. To enable a large number of conditions to be screened,
the post-thaw growth rate of E. coli was also followed by OD600
(turbidity) measurements, which enable higher throughput
measurements in 96-well plates. E. coli was frozen with the
indicated formulations and post-thaw inoculated into LB
media, and their growth was monitored. After seven freeze−
thaw cycles in liquid nitrogen, cells cryopreserved in 25%
glycerol and PEG/PVA (100 and 1 mg mL−1, respectively) had
essentially identical growth rates (Figure 5), which were faster
than all the other formulations used.
By monitoring growth proﬁles of E. coli, various formulations
and molecular weights of PVA were also tested for their
eﬃcacy (Figures S5−S7). For PVA, 10 and 31 kDa gave
approximately identical recovery levels. However, 10 kDa is
easier to dissolve into buﬀer, making it preferable for real
applications where concentrated stock solutions are required.
Higher molecular weight PVA can also lead to dynamic ice-
shaping which is known to reduce recovery of cells post-
thaw.23 Lower molecular weight PEGs (200−1500 Da) alone
appeared to have a slightly greater cryoprotective eﬀect than
larger PEGs (4−8 kDa), as they reach a higher OD600 and
display slower logarithmic decline phases, indicating improved
cell health, but these diﬀerences were small (Figure S6).
Various permutations of PEG/PVA were also screened (Figure
S7), and in all cases addition of PVA increased the
cryoprotective eﬀect and lengthened the stationary phase of
cells. The improvement was most signiﬁcant in the case of
larger PEGs. Considering the cryoprotective eﬀect of each of
the mixtures, and the solubility of each of the constituents, it
was determined that 10 kDa PVA and 4 kDa PEG were the
optimum molecular masses out of the 18 formulations we
tested to use to ensure reliable and easy to use
cryopreservation.
As a ﬁnal test, the eﬀect of storage at −20 °C in a standard
laboratory freezer after ﬁrst snap freezing (−80 °C) was also
studied after 1 and 4 weeks of storage (Figure S4). It was
found that bacterial recovery was similar for 25% glycerol and
PEG/PVA after 1 week storage, which supports the use of this
method for routine laboratory manipulations. For 4 week
storage we noted that the glycerol formulation yielded more
colonies, but this was not optimized, and signiﬁcant recovery
was still possible with the polymer-only mixture. It should be
noted that the glycerol solution did not fully freeze at −20 °C,
thus providing a carbon source to the E. coli.
■ CONCLUSIONS
This study reports a disruptive approach to store bacteria in
the frozen state through modulation of ice recrystallization
with synthetic polymer formulations, which mimic antifreeze
proteins used in nature to survive extreme environments. It is
shown that PEG/PVA mixtures provide a synergistic eﬀect
with the number of recovered bacterial colonies after seven
freeze−thaw cycles being up to 4-fold higher than the current
gold standard of glycerol. Confocal microscopy showed that
similar numbers of bacteria with intact membranes are
recovered for both systems but that the polymer cryopro-
tectants lead to more viable colonies, suggesting their lower
toxicity is crucial. This new cryopreservation approach is
shown to be suitable for a range of bacterial genera including
Gram-negative/positive and mycobacteria. It was found that
the synergistic eﬀect on cell survival was linked to PVAs ice
recrystallization activity and the PEG bulking agent, as addition
of type III antifreeze proteins (at similar total IRI activity) also
enabled cryopreservation, although these proteins are signiﬁ-
cantly more expensive and not practical for routine
cryopreservation compared to the polymer formulations.
These results highlight the contrast with traditional solvent-
based cryoprotectants which function by distinct mechanisms.
Optimal conditions for use of this system in a laboratory or
application-focused environment are presented, and as both
PEG and PVA are commodity polymers available as food
grade,45,46 this system will have wide application across
molecular biology, microbiome research, and for translation
into the food or biotechnology industry, which are under-
pinned by the storage and transport of speciﬁc bacterial strains.
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acs.bio-
mac.8b00660.
Figure 4. Normalized cell recovery for three diﬀerent bacteria upon
addition of diﬀerent cryoprotectants after seven freeze (−196 °C)−
thaw (20 °C) cycles (red = control, blue = glycerol, black = PEG/
PVA). Values obtained are normalized to themselves.
Figure 5. E. coli growth proﬁles after seven freeze (−196 °C)−thaw
(20 °C) cycles and then inoculation into LB media.
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